GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE292nnn/GSE292717/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292717GEOGSEfalseSuper-enhancers-driven SOX4/SMAD3 enhances AXL signaling via membrane phospholipid remodeling to accelerate leukemia progression [RNA-Seq]Cancer often involves aberrant epigenetic activation. In CML-BP, super - enhancer - driven SOX4 and SMAD3 form an auto - regulatory axis. They co - regulate epigenome, activate AXL - related pathways, and mediate membrane phospholipid remodeling. Bemcentinib, an AXL inhibitor, can inhibit CML - BP progression. SOX4/SMAD3 are key factors and Bemcentinib a potential therapy.2026/05/15GSE292717GSM9034437GSM9034436GSM9034435GSM9034434GSM8864130GSM8864137GSM8864115GSM8864138GSM8864116GSM8864135GSM8864113GSM8864114GSM8864136GSM8864133GSM8864111GSM8864112GSM8864134GSM8864131GSM8864132GSM8864110GSM8864119GSM8864117GSM8864139GSM8864118GSM8864140GSM8864126GSM8864127GSM8864105GSM8864124GSM8864125GSM8864122GSM8864123GSM8864120GSM8864121GSM9034439GSM9034438GSM8864108GSM8864109GSM8864106GSM8864128GSM8864129GSM886410729480292717Homo sapiens[41721601]